Abeona Therapeutics Inc. (PCJ)
XSTU 
Summary
PCJ Chart
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity
Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed analyst expectations, leading to a 14% stock drop. Operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, highlight a steep learning curve, but management expects improvement as experience grows. Partnered programs with Ultragenyx and Taysha offer potential near-term catalysts, with milestone and royalty payments possible if approvals and sales targets are met.
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics Q2 Earnings Call Highlights
Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.
Abeona Therapeutics Inc. (PCJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Abeona Therapeutics Inc. ever had a stock split?
Abeona Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Vishwas Seshadri CEO | XSTU Exchange | US00289Y2063 ISIN |
| US Country | 226 Employees | - Last Dividend | 5 Jul 2022 Last Split | 19 Sep 1980 IPO Date |
Overview
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing its efforts on the development of gene and cell therapies aimed at treating life-threatening diseases. Founded as PlasmaTech Biopharmaceuticals, Inc., it underwent a rebranding to Abeona Therapeutics Inc. in June 2015, aligning its identity more closely with its ambitious goals. The company leverages cutting-edge scientific research and technology to create breakthrough treatments, with a primary operational base in Cleveland, Ohio. Abeona's work represents a beacon of hope for patients with few to no therapeutic options, as it pioneers in the advances of medical science towards curing previously untreatable genetic conditions.
Products and Services
- EB-101 - Abeona’s forefront product, an autologous, engineered cell therapy undergoing Phase III clinical trial specifically designed for treating recessive dystrophic epidermolysis bullosa. This severe genetic disorder causes the skin to be very fragile and to blister easily. EB-101 aims to correct the genetic defect in the patients' skin cells, potentially providing a transformative and long-lasting treatment.
- ABO-503 - A developmental therapy targeting X-linked retinoschisis, a genetic eye condition that leads to vision loss. Abeona is exploring gene therapy approaches to possibly restore or stabilize vision for those affected by this condition, showcasing their commitment to addressing rare and underserved ophthalmological diseases.
- ABO-504 - Aimed at treating stargardt disease, which is the most common form of inherited juvenile macular degeneration, leading to progressive vision loss. Through ABO-504, Abeona seeks to intervene in the disease's progression, potentially preserving or improving vision for patients suffering from this devastating condition.
- ABO-505 - Designed for the treatment of autosomal dominant optic atrophy, the most common inherited optic nerve disorder, which can significantly impair visual acuity. This initiative reflects Abeona’s dedication to combating optical disorders through innovative gene therapy solutions, offering hope to those with limited treatment options.
- AAV-based Gene Therapy - Through its AIM vector platform programs, Abeona is advancing the development of adeno-associated virus (AAV) based gene therapies for a range of diseases. This versatile platform underscores the company’s broad approach to tackling genetic disorders, representing a key element in its strategy to lead in the biopharmaceutical sector with pioneering treatments.
